Current evidence shows no lower serious-adverse-event rate for triple agonists.

The Claim

Investigational glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP)/glucagon triple-receptor agonists have a lower rate of serious adverse events than GLP-1 receptor agonist medications.

Verified by Lenz · Aug 26, 2026

The Short Version

Available evidence does not establish that triple-receptor agonists cause fewer serious adverse events than GLP-1 receptor agonists. Reported estimates are generally similar, statistically inconclusive, or based on placebo comparisons rather than direct comparisons with GLP-1 medications. Evidence also comes predominantly from retatrutide studies, so it cannot support a class-wide safety advantage.

Caveats

Confidence or credible intervals around lower point estimates cross 1, so the apparent reductions are not statistically established.
Results from comparisons with placebo cannot demonstrate lower risk than GLP-1 receptor agonists.
Most available safety evidence concerns retatrutide and should not be generalized to every investigational triple agonist.

The Receipts

+ 25 more sources — see the full list on Lenz

Filed Under

Glucagon-Like Peptide-1 (GLP-1)/Glucose-Dependent Insulinotropic Polypeptide (GIP)/Glucagon Triple-Receptor AgonistsGlucagon-Like Peptide-1 (GLP-1) Receptor AgonistsSerious Adverse Events

Current evidence shows no lower serious-adverse-event rate for triple agonists.

The Short Version

Caveats

The Receipts

Filed Under

More Fact Checks

Clinical evidence shows GLP-1 agonists’ cardiovascular and metabolic benefits usually outweigh side effects.

Large trials show semaglutide lowers major cardiovascular events in obese CVD patients.

Semaglutide has documented ocular risks, including rare vision-threatening NAION.

U.S. adult obesity fell from about 42.8% in 2017–2018 to 40.3% in 2021–2023.